How is Belzutifan administered?

The recommended belzutifan dosage is 120 mg administered orally once daily with or without food.

Is Belzutifan FDA approved?

A new drug recently approved by the Food and Drug Administration (FDA) may help people with VHL avoid or delay surgery by shrinking their tumors. On August 13, FDA approved belzutifan (Welireg) to treat adults who have several tumors associated with VHL.

What kind of drug is Belzutifan?

Belzutifan is in a class of medications called hypoxia-inducible factor inhibitors. It works by blocking the activity of a certain protein in people with VHL.

How long can someone with VHL live?

Many studies indicated that the survival of VHL disease patients was worse than the general population. A study in 1990 showed that the median survival was 49 years (14). A recent study reported the estimated life expectancy for male and female patients was 67 and 60 years, respectively (15).

How do you cure VHL?

Treatment of most cases of VHL usually involves surgery to remove the tumors before they become harmful. Certain tumors can be treated with focused high-dose irradiation. Individuals with VHL need careful monitoring by a physician and/or medical team familiar with the disorder.

What type of drug is belzutifan?

What very common side effect does Belzutifan Welireg cause?

The most common (≥25%) adverse reactions, including laboratory abnormalities, that occurred in patients who received WELIREG were decreased hemoglobin, anemia, fatigue, increased creatinine, headache, dizziness, increased glucose, and nausea.

What is Welireg?

Welireg is a prescription medicine used to treat the symptoms of Von Hippel-Lindau Disease (VHL). Welireg may be used alone or with other medications. Welireg belongs to a class of drugs called Hypoxia-Inducible Factors Inhibitors. It is not known if Welireg is safe and effective in children.

When is belzutifan available?

On August 13, 2021, the US Food and Drug Administration (FDA) approved Belzutifan [pronounced bell-ZOO-ti-fan] (Welireg) for the treatment of renal cell carcinoma (RCC), pancreatic neuroendocrine tumors (pNET) and hemangioblastomas (HB) in adult VHL patients. The medication is now available to be prescribed in the US.

What is belzutifan used for?

It is used to help treat certain tumors/growths caused by this disease that do not need surgery right away (such as in the kidneys, pancreas, brain/spinal cord). Belzutifan works by slowing or stopping the growth of tumor cells.